HOUSE BILL 137

57TH LEGISLATURE - STATE OF NEW MEXICO - SECOND SESSION, 2026

INTRODUCED BY

Elizabeth "Liz" Thomson

AN ACT

RELATING TO OPIOIDS; REQUIRING RETAIL PHARMACIES TO KEEP STOCKS OF CERTAIN TYPES OF DRUGS THAT TREAT OPIOID USE DISORDER; REQUIRING WHOLESALE DRUG DISTRIBUTORS TO REPORT INSTANCES IN WHICH THE DISTRIBUTORS DO NOT FILL ORDERS FOR BUPRENORPHINE MADE BY RETAIL PHARMACIES; REQUIRING REPORTS; PROVIDING PENALTIES; MAKING AN APPROPRIATION.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:

SECTION 1. A new section of the New Mexico Drug, Device and Cosmetic Act is enacted to read:

"[NEW MATERIAL] BUPRENORPHINE STOCKING REQUIREMENTS.--

A. At least once every thirty days, a retail pharmacy that stocks controlled substances shall compute the retail pharmacy's minimum daily buprenorphine stocking requirement by determining the average amount of buprenorphine

underscored material = new
[~~bracketed material~~] = delete

dispensed to ultimate users per day in the previous thirty days, rounding to the nearest milligram. A retail pharmacy that is not a community-based pharmacy shall maintain a stock of buprenorphine sufficient to satisfy the minimum daily buprenorphine stocking requirement, plus at least three additional prescriptions for buprenorphine, including at least one prescription for buprenorphine that is a buprenorphine monoproduct and one prescription for buprenorphine that is a buprenorphine-naloxone combination product. A retail pharmacy that is a community-based pharmacy shall maintain a stock of buprenorphine that is at least equal to either the pharmacy's minimum daily buprenorphine stocking requirement plus one additional prescription for buprenorphine or two prescriptions for buprenorphine, whichever is greater. A retail pharmacy that fails to satisfy the stocking requirements of this section is not in violation of this section if the retail pharmacy takes any of the following actions within three days of failing to satisfy the stocking requirements:

(1) ordering a replacement stock of buprenorphine sufficient to satisfy the stocking requirements of this section; or

(2) requesting a wholesale drug distributor to increase the retail pharmacy's allotment of buprenorphine, and:

(a) once the wholesale drug distributor approves the request, ordering a replacement stock of

underscored material = new
[~~bracketed material~~] = delete

buprenorphine within three days of receiving the approval; or

(b) the wholesale drug distributor denies the request.

B. A retail pharmacy shall maintain records of the retail pharmacy's minimum daily buprenorphine stocking requirements. Records shall be maintained for a period of at least three years from the date of the record and may be inspected as required by authorized agents of the board.

C. A wholesale drug distributor shall report to the board on a monthly basis, in a form and manner prescribed by the board, each instance in which the wholesale drug distributor:

(1) denied, in whole or in part, an order for buprenorphine submitted by a retail pharmacy;

(2) delayed an order for buprenorphine submitted by a retail pharmacy due to the retail pharmacy's threshold of buprenorphine; or

(3) denied a request by a retail pharmacy to increase the retail pharmacy's threshold of buprenorphine.

D. A report submitted by a wholesale drug distributor pursuant to this subsection shall include:

(1) the name of the retail pharmacy affected;

(2) the date on which the retail pharmacy submitted the order for buprenorphine or requested an increase to the retail pharmacy's threshold of buprenorphine;

underscored material = new
[~~bracketed material~~] = delete

(3) the date on which the wholesale drug distributor denied or delayed the retail pharmacy's order for buprenorphine or denied the requested increase in the retail pharmacy's threshold of buprenorphine;

(4) the reason the wholesale drug distributor denied or delayed the retail pharmacy's order for buprenorphine or denied the requested increase in the retail pharmacy's threshold of buprenorphine; and

(5) any other information required by the board.

E. The board shall submit data gathered pursuant to this section to the department of health. The department of health shall analyze the data and publish a biannual report on access to buprenorphine in retail pharmacies. The report shall include:

(1) information on the frequency with which each wholesale drug distributor:

(a) denied a retail pharmacy's order for buprenorphine;

(b) delayed a retail pharmacy's order for buprenorphine due to the retail pharmacy's threshold of buprenorphine; or

(c) denied a retail pharmacy's requested increase in the retail pharmacy's threshold of buprenorphine;

(2) aggregated data on the reasons reported by

underscored material = new
[~~bracketed material~~] = delete

wholesale drug distributors for denying a retail pharmacy's order for buprenorphine or a request by a retail pharmacy to increase the retail pharmacy's threshold of buprenorphine; and

(3) any other information that the department of health deems appropriate.

F. Reports published pursuant to Subsection E of this section shall not include information that could identify individual retail pharmacies and shall comply with state and federal privacy and confidentiality laws, rules and regulations.

G. When the board or the department of health is required by law, including the Inspection of Public Records Act, to disclose information gathered pursuant to this section, the board or the department of health shall redact information gathered pursuant to Subsection C of this section that could identify an individual retail pharmacy.

H. The board may impose the following penalties on retail pharmacies that violate this section:

(1) for a first or second violation, notice of the violation that includes information on the requirements to comply with this section;

(2) for a third violation within a thirty-six-month period, a directed plan of correction to help the retail pharmacy remain compliant with the requirements of this section; and

underscored material = new
[~~bracketed material~~] = delete

(3) for a fourth violation or any subsequent violation within a thirty-six-month period following the previous violation, a fine not to exceed two thousand five hundred dollars ($2,500).

I. The board may impose the following penalties on wholesale drug distributors that violate this section:

(1) for a first violation, notice of the violation that includes information on the requirements to comply with this section; and

(2) for a second violation or any subsequent violation within a thirty-six-month period following the previous violation, a fine not to exceed ten thousand dollars ($10,000).

J. A retail pharmacy shall not be penalized for a violation of this section if the violation is solely attributable to the action of a wholesale drug distributor. A retail pharmacy may conclusively establish that a violation of this section is solely attributable to the action of a wholesale drug distributor by demonstrating compliance with Paragraph (1) or (2) of Subsection A of this section.

K. As used in this section:

(1) "buprenorphine" means the drug buprenorphine, including any official, generic or chemical name used to describe buprenorphine prescribed for the treatment of opioid use disorder;

underscored material = new
[~~bracketed material~~] = delete

(2) "community-based pharmacy" means a retail pharmacy that is:

(a) open to the public for prescriptions to be filled, regardless of the facility or practice where the prescription was written; and

(b) not: 1) government-owned; 2) hospital-owned; 3) owned by a corporation that owns hospitals; 4) an extension of a medical practice or special facility; 5) owned by a corporate chain of pharmacies with stores outside of the state; or 6) a mail-order pharmacy;

(3) "minimum daily buprenorphine stocking requirement" means the average number of milligrams of buprenorphine dispensed to ultimate users by a retail pharmacy per day over a thirty-day period, in formulations, dosages and brand names consistent with the prescriptions for buprenorphine dispensed to ultimate users by the retail pharmacy during the thirty-day period;

(4) "prescription for buprenorphine" means sufficient buprenorphine in tablet or film form to provide a patient with twenty-four milligrams per day for two weeks;

(5) "retail pharmacy" means a pharmacy physically located, and licensed to dispense drugs, in the state;

(6) "ultimate user" means a person who lawfully possesses buprenorphine for the person's own use or

underscored material = new
[~~bracketed material~~] = delete

for the use of a member of the person's household; and

(7) "wholesale drug distributor" means a person licensed to engage in the wholesale distribution of prescription drugs in the state."

SECTION 2. APPROPRIATION.--One million five hundred thousand dollars ($1,500,000) is appropriated from the general fund to the health care authority for expenditure in fiscal year 2027 to increase medicaid reimbursement rates for buprenorphine prescriptions. Any unexpended balance remaining at the end of fiscal year 2027 shall revert to the general fund.

underscored material = new
[~~bracketed material~~] = delete